Is MTNB or NAMS more undervalued in 2026?

CirclFi compares Matinas Biopharma Holdings, Inc (MTNB) and NewAmsterdam Pharma Company N.V (NAMS) using 13 institutional-grade valuation models. MTNB has a Quality of Company score of 4.0/10 while NAMS scores 2.3/10.

Which is a better buy — MTNB or NAMS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MTNB and NAMS valuations compare?

MTNB at $0.79 and NAMS at $35.42 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MTNB vs NAMS Valuation Comparison 2026 — Intrinsic Value Analysis

MTNB

Biotechnology

Matinas Biopharma Holdings, Inc

Quality

4.0

out of 10

Value Trap

LOW

Price

$0.79

Last close

Models

7/13

Active

NAMS

Biotechnology

NewAmsterdam Pharma Company N.V

Quality

2.3

out of 10

Value Trap

—

Price

$35.42

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	MTNB Fair Value	MTNB Upside	NAMS Fair Value	NAMS Upside
Bayesian DCF	Intrinsic	$0.47	-40.9%	$7.68	-78.3%
Earnings Power Value	Intrinsic	—	—	$18.09	-39.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.08	+287.3%	$2.99	-91.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MTNB vs NAMS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MTNB vs NAMS — Which Stock Is More Undervalued?

MTNB scores higher with a 4.0/10 quality rating vs NAMS's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Matinas Biopharma Holdings, Inc (MTNB) and NewAmsterdam Pharma Company N.V (NAMS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MTNB currently trades at $0.79 with a QOC of 4.0/10, while NAMS trades at $35.42 with a QOC of 2.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).